Predisposing factors, pathogenesis and therapeutic intervention of Kawasaki disease

Drug Discovery Today

Volumn 21, Issue 11, 2016, Pages 1850-1857

  Galeotti, Caroline ^a,b,c,d   Kaveri, Srini V ^a,b,c,e   Cimaz, Rolando ^f   Koné Paut, Isabelle ^d   Bayry, Jagadeesh ^a,b,c,e  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d BICÊTRE HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METHOTREXATE; PREDNISOLONE;

GENETIC PREDISPOSITION; HUMAN; IMMUNOREGULATION; INFECTION; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; PATHOGENESIS; PLASMA EXCHANGE; REVIEW; STANDARD; ANIMAL; DISEASE PREDISPOSITION; GENETICS; IMMUNOLOGY; RISK FACTOR;

ANIMALS; DISEASE SUSCEPTIBILITY; HUMANS; MUCOCUTANEOUS LYMPH NODE SYNDROME; RISK FACTORS;

EID: 84994608353     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2016.08.004     Document Type: Review

References (98)

1. 1 Kawasaki, T., Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi 16 (1967), 178–222 (in Japanese).
2. 2 Fraison, J.B., et al. Kawasaki disease in adults: observations in France and literature review. Autoimmun. Rev. 15 (2016), 242–249.
3. 3 Orenstein, J.M., et al. Three linked vasculopathic processes characterize Kawasaki disease: a light and transmission electron microscopic study. PLoS One, 7, 2012, e38998.
4. 4 Onouchi, Y., Genetics of Kawasaki disease: what we know and don't know. Circ. J. 76 (2012), 1581–1586.
5. 5 Rowley, A.H., et al. Ultrastructural, immunofluorescence, and RNA evidence support the hypothesis of a new virus associated with Kawasaki disease. J. Infect. Dis. 203 (2011), 1021–1030.
6. 6 Abe, J., et al. Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease. J. Immunol. 174 (2005), 5837–5845.
7. 7 Alphonse, M.P., et al. Inositol 1,4,5 triphosphate 3-kinase C regulates NLRP3 inflammasome activation in Kawasaki disease. Circulation, 131, 2015, A021.
8. 8 Burns, J.C., et al. Seasonality of Kawasaki disease: a global perspective. PLoS One, 8, 2013, e74529.
9. 9 Uehara, R., Belay, E.D., Epidemiology of Kawasaki disease in Asia, Europe, and the United States. J. Epidemiol. 22 (2012), 79–85.
10. 10 Rowley, A.H., et al. IgA plasma cell infiltration of proximal respiratory tract, pancreas, kidney, and coronary artery in acute Kawasaki disease. J. Infect. Dis. 182 (2000), 1183–1191.
11. 11 Rowley, A.H., et al. Cytoplasmic inclusion bodies are detected by synthetic antibody in ciliated bronchial epithelium during acute Kawasaki disease. J. Infect. Dis. 192 (2005), 1757–1766.
12. 12 Meissner, H.C., Leung, D.Y., Superantigens, conventional antigens and the etiology of Kawasaki syndrome. Pediatr. Infect. Dis. J. 19 (2000), 91–94.
13. 13 Nomura, Y., et al. Maternal antibody against toxic shock syndrome toxin-1 may protect infants younger than 6 months of age from developing Kawasaki syndrome. J. Infect. Dis. 185 (2002), 1677–1680.
14. 14 Chang, L.Y., et al. Viral infections associated with Kawasaki disease. J. Formos. Med. Assoc. 113 (2014), 148–154.
15. 15 Lee, K.Y., et al. Kawasaki disease may be a hyperimmune reaction of genetically susceptible children to variants of normal environmental flora. Med. Hypotheses 69 (2007), 642–651.
16. 16 Huang, W.C., et al. Epidemiologic features of Kawasaki disease in Taiwan, 2003–2006. Pediatrics 123 (2009), e401–e405.
17. 17 Kim, G.B., et al. Epidemiologic features of Kawasaki disease in South Korea: data from nationwide survey, 2009–2011. Pediatr. Infect. Dis. J. 33 (2014), 24–27.
18. 18 Makino, N., et al. Descriptive epidemiology of Kawasaki disease in Japan, 2011–2012: from the results of the 22nd nationwide survey. J. Epidemiol. 25 (2015), 239–245.
19. 19 Lee, Y.C., et al. Two new susceptibility loci for Kawasaki disease identified through genome-wide association analysis. Nat. Genet. 44 (2012), 522–525.
20. 20 Onouchi, Y., et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat. Genet. 40 (2008), 35–42.
21. 21 Onouchi, Y., et al. Common variants in CASP3 confer susceptibility to Kawasaki disease. Hum. Mol. Genet. 19 (2010), 2898–2906.
22. 22 Onouchi, Y., et al. A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat. Genet. 44 (2012), 517–521.
23. 23 Shimizu, C., et al. Transforming growth factor-beta signaling pathway in patients with Kawasaki disease. Circ. Cardiovasc. Genet. 4 (2011), 16–25.
24. 24 Kuo, H.C., et al. Single-nucleotide polymorphism rs7251246 in ITPKC is associated with susceptibility and coronary artery lesions in Kawasaki disease. PLoS One, 9, 2014, e91118.
25. 25 Kuo, H.C., et al. CASP3 gene single-nucleotide polymorphism (rs72689236) and Kawasaki disease in Taiwanese children. J. Hum. Genet. 56 (2011), 161–165.
26. 26 Khor, C.C., et al. Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. Nat. Genet. 43 (2011), 1241–1246.
27. 27 Kuo, H.C., et al. Genome-wide association study identifies novel susceptibility genes associated with coronary artery aneurysm formation in Kawasaki disease. PLoS One, 11, 2016, e0154943.
28. 28 Lee, Y., et al. Interleukin-1beta is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease. Circulation 125 (2012), 1542–1550.
29. 29 Lee, Y., et al. IL-1 signaling is critically required in stromal cells in Kawasaki disease vasculitis mouse model: role of both IL-1α and IL-1β. Arterioscler. Thromb. Vasc. Biol. 35 (2015), 2605–2616.
30. 30 Lee, K.Y., A common immunopathogenesis mechanism for infectious diseases: the protein-homeostasis-system hypothesis. Infect. Chemother. 47 (2015), 12–26.
31. 31 Yoshimura, K., et al. Increased nitric oxide production by neutrophils in early stage of Kawasaki disease. Eur. J. Pediatr. 168 (2009), 1037–1041.
32. 32 Grunebaum, E., et al. The role of anti-endothelial cell antibodies in Kawasaki disease – in vitro and in vivo studies. Clin. Exp. Immunol. 130 (2002), 233–240.
33. 33 Leung, D.Y., et al. Two monokines, interleukin 1 and tumor necrosis factor, render cultured vascular endothelial cells susceptible to lysis by antibodies circulating during Kawasaki syndrome. J. Exp. Med. 164 (1986), 1958–1972.
34. 34 Kuo, H.C., et al. Identification of an association between genomic hypomethylation of FCGR2A and susceptibility to Kawasaki disease and intravenous immunoglobulin resistance by DNA methylation array. Arthritis Rheumatol. 67 (2015), 828–836.
35. 35 Lin, C.Y., et al. Serial changes of serum interleukin-6, interleukin-8, and tumor necrosis factor α among patients with Kawasaki disease. J. Pediatr. 121 (1992), 924–926.
36. 36 Leung, D.Y., et al. Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet 334 (1989), 1298–1302.
37. 37 Wang, Y., et al. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease. Arthritis Rheum. 65 (2013), 805–814.
38. 38 Jia, S., et al. The T helper type 17/regulatory T cell imbalance in patients with acute Kawasaki disease. Clin. Exp. Immunol. 162 (2010), 131–137.
39. 39 Newburger, J.W., et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 110 (2004), 2747–2771.
40. 40 Galeotti, C., et al. Molecular and immunological biomarkers to predict IVIg response. Trends Mol. Med. 21 (2015), 145–147.
41. 41 Greco, A., et al. Kawasaki disease: an evolving paradigm. Autoimmun. Rev. 14 (2015), 703–709.
42. 42 Newburger, J.W., et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N. Engl. J. Med. 324 (1991), 1633–1639.
43. 43 Galeotti, C., et al. Kawasaki disease: aetiopathogenesis and therapeutic utility of intravenous immunoglobulin. Autoimmun. Rev. 9 (2010), 441–448.
44. 44 Burns, J.C., Franco, A., The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease. Expert Rev. Clin. Immunol. 11 (2015), 819–825.
45. 45 Tha-In, T., et al. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol. 29 (2008), 608–615.
46. 46 Trinath, J., et al. Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells. Blood 122 (2013), 1419–1427.
47. 47 Othy, S., et al. Intravenous gammaglobulin inhibits encephalitogenic potential of pathogenic T cells and interferes with their trafficking to the central nervous system, implicating sphingosine-1 phosphate receptor 1-mammalian target of rapamycin axis. J. Immunol. 190 (2013), 4535–4541.
48. 48 Schwab, I., Nimmerjahn, F., Intravenous immunoglobulin therapy: how does IgG modulate the immune system?. Nat. Rev. Immunol. 13 (2013), 176–189.
49. 49 Maddur, M.S., et al. Comparison of different IVIg preparations on IL-17 production by human Th17 cells. Autoimmun. Rev. 10 (2011), 809–810.
50. 50 Ballow, M., The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J. Allergy Clin. Immunol. 127 (2011), 315–323.
51. 51 Sharma, M., et al. Intravenous immunoglobulin-induced IL-33 is insufficient to mediate basophil expansion in autoimmune patients. Sci. Rep., 4, 2014, 5672.
52. 52 Kessel, A., et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J. Immunol. 179 (2007), 5571–5575.
53. 53 Bayry, J., et al. Intravenous immunoglobulin expands regulatory T cells in autoimmune rheumatic disease. J. Rheumatol. 39 (2012), 450–451.
54. 54 Maddur, M.S., et al. Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain–Barre syndrome patients. Immunologic. Res. 60 (2014), 320–329.
55. 55 Fiebiger, B.M., et al. Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), E2385–E2394.
56. 56 Othy, S., et al. Sialylation may be dispensable for reciprocal modulation of helper T cells by intravenous immunoglobulin. Eur. J. Immunol. 44 (2014), 2059–2063.
57. 57 Maddur, M.S., et al. Intravenous immunoglobulin-mediated expansion of regulatory T cells in autoimmune patients is associated with increased prostaglandin E2 levels in the circulation. Cell. Mol. Immunol. 12 (2015), 650–652.
58. 58 Seite, J.F., et al. What is the contents of the magic draft IVIg?. Autoimmun. Rev. 7 (2008), 435–439.
59. 59 Lin, I.C., et al. Augmented TLR2 expression on monocytes in both human Kawasaki disease and a mouse model of coronary arteritis. PLoS One, 7, 2012, e38635.
60. 60 Galeotti, C., et al. Heme oxygenase-1 is dispensable for the anti-inflammatory activity of intravenous immunoglobulin. Sci. Rep., 6, 2016, 19592.
61. 61 Gupta, M., et al. Cytokine modulation with immune gamma-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment. J. Clin. Immunol. 21 (2001), 193–199.
62. 62 Rasouli, M., et al. Downregulation of Th17 cells and the related cytokines with treatment in Kawasaki disease. Immunol. Lett. 162 (2014), 269–275.
63. 63 Guo, M.M., et al. Th17- and Treg-related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease. Allergy 70 (2015), 310–318.
64. 64 Ichiyama, T., et al. Intravenous immunoglobulin inhibits NF-κB activation and affects Fcγ receptor expression in monocytes/macrophages. Naunyn Schmiedebergs Arch. Pharmacol. 369 (2004), 428–433.
65. 65 Ichiyama, T., et al. Intravenous immunoglobulin does not increase FcγRIIB expression on monocytes/macrophages during acute Kawasaki disease. Rheumatology 44 (2005), 314–317.
66. 66 Sleeper, L.A., et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J. Pediatr. 158 (2011), 831–835 e833.
67. 67 Singh, S., et al. Management of Kawasaki disease in resource-limited settings. Pediatr. Infect. Dis. J. 34 (2015), 94–96.
68. 68 Baumer, J.H., et al. Salicylate for the treatment of Kawasaki disease in children. Cochrane Database Syst. Rev., 2006, 2006, CD004175.
69. 69 Terai, M., Shulman, S.T., Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J. Pediatr. 131 (1997), 888–893.
70. 70 Ogata, S., et al. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial. Pediatrics 129 (2012), e17–e23.
71. 71 Tremoulet, A.H., et al. Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease. J. Pediatr., 161, 2012 506–512; e501.
72. 72 Hokosaki, T., et al. Long-term efficacy of plasma exchange treatment for refractory Kawasaki disease. Pediatr. Int. 54 (2012), 99–103.
73. 73 Eleftheriou, D., et al. Management of Kawasaki disease. Arch. Dis. Child. 99 (2014), 74–83.
74. 74 Furukawa, T., et al. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch. Dis. Child. 93 (2008), 142–146.
75. 75 Hashino, K., et al. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr. Int. 43 (2001), 211–217.
76. 76 Miura, M., et al. Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. Eur. J. Pediatr. 167 (2008), 1119–1123.
77. 77 Ogata, S., et al. The strategy of immune globulin resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. J. Cardiol. 53 (2009), 15–19.
78. 78 Kobayashi, T., et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 379 (2012), 1613–1620.
79. 79 Tremoulet, A.H., et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet 383 (2014), 1731–1738.
80. 80 Burns, J.C., et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J. Pediatr. 153 (2008), 833–838.
81. 81 Mori, M., et al. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series. J. Rheumatol. 39 (2012), 864–867.
82. 82 Son, M.B., et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J. Pediatr., 158, 2011 644–649; e641.
83. 83 Youn, Y., et al. Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatr. Infect. Dis. J. 35 (2016), 457–459.
84. 84 Hamada, H., et al. Inflammatory cytokine profiles during cyclosporin treatment for immunoglobulin-resistant Kawasaki disease. Cytokine 60 (2012), 681–685.
85. 85 Suzuki, H., et al. Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin. Pediatr. Infect. Dis. J. 30 (2011), 871–876.
86. 86 Ahn, S.Y., Kim, D.S., Treatment of intravenous immunoglobulin-resistant Kawasaki disease with methotrexate. Scand. J. Rheumatol. 34 (2005), 136–139.
87. 87 Lee, T.J., et al. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease. Yonsei Med. J. 49 (2008), 714–718.
88. 88 Garg, N., et al. Rosuvastatin improves endothelial dysfunction in ankylosing spondylitis. Clin. Rheumatol. 34 (2015), 1065–1071.
89. 89 Yoshimura, K., et al. Inhibitory effect of statins on inflammation-related pathways in human abdominal aortic aneurysm tissue. Int. J. Mol. Sci. 16 (2015), 11213–11228.
90. 90 Wallace, C.A., et al. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics, 105, 2000, E78.
91. 91 Cohen, S., et al. A child with severe relapsing Kawasaki disease rescued by IL-1 receptor blockade and extracorporeal membrane oxygenation. Ann. Rheum. Dis. 71 (2012), 2059–2061.
92. 92 Shafferman, A., et al. High dose anakinra for treatment of severe neonatal Kawasaki disease: a case report. Pediatr. Rheumatol. Online J., 12, 2014, 26.
93. 93 Miettunen, P.M., et al. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology 50 (2011), 417–419.
94. 94 Chen, S., et al. Marked acceleration of atherosclerosis after Lactobacillus casei-induced coronary arteritis in a mouse model of Kawasaki disease. Arterioscler. Thromb. Vasc. Biol. 32 (2012), e60–e71.
95. 95 Tremoulet, A.H., et al. Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial). Contemp. Clin. Trials 48 (2016), 70–75.
96. 96 Mori, M., et al. Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma-globulin. Mod. Rheumatol. 14 (2004), 43–47.
97. 97 Coll, R.C., et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 21 (2015), 248–255.
98. 98 Wannamaker, W., et al. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoy l)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1β and IL-18. J. Pharmacol. Exp. Ther. 321 (2007), 509–516.